Since neoplastic B cells are reportedly capable of differentiating into mesenchymal cells, it is possible that these PD-L1-expressing dendritic cell neoplasms are derived from malignant B cells that have experienced transdifferentiation, and that share pathogenetic mechanisms with CHLs. This evidence concerns the gene CD274 and dendritic cell tumor.